Protocol Ledger

NCT05523167 · Phase II/III · COMPLETED

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

Interventional Phase II/III clinical trial protocol NCT05523167 sponsored by argenx in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-12 Enrollment: 265 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05523167
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)265 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05523167
Protocol FieldVerified Registry Value
NCT IdentifierNCT05523167
Consolidated Lead Sponsorargenx
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment265 participants (ACTUAL)
Registered Start Date2022-10-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI